NO20052059L - Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta. - Google Patents

Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.

Info

Publication number
NO20052059L
NO20052059L NO20052059A NO20052059A NO20052059L NO 20052059 L NO20052059 L NO 20052059L NO 20052059 A NO20052059 A NO 20052059A NO 20052059 A NO20052059 A NO 20052059A NO 20052059 L NO20052059 L NO 20052059L
Authority
NO
Norway
Prior art keywords
interferon
therapies
beta
chronic inflammatory
inflammatory demyelinating
Prior art date
Application number
NO20052059A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052059D0 (no
Inventor
Alfred Sandrock
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20052059D0 publication Critical patent/NO20052059D0/no
Publication of NO20052059L publication Critical patent/NO20052059L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20052059A 2002-09-27 2005-04-27 Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta. NO20052059L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41430702P 2002-09-27 2002-09-27
PCT/US2003/030532 WO2004028472A2 (en) 2002-09-27 2003-09-26 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β

Publications (2)

Publication Number Publication Date
NO20052059D0 NO20052059D0 (no) 2005-04-27
NO20052059L true NO20052059L (no) 2005-06-27

Family

ID=32043377

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052059A NO20052059L (no) 2002-09-27 2005-04-27 Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.

Country Status (21)

Country Link
US (2) US20060182715A1 (zh)
EP (1) EP1575531B9 (zh)
JP (3) JP2006513990A (zh)
KR (1) KR20050059195A (zh)
CN (2) CN1802170A (zh)
AT (1) ATE520412T1 (zh)
AU (1) AU2003277006C1 (zh)
BR (1) BR0314548A (zh)
CA (1) CA2500189A1 (zh)
DK (1) DK1575531T3 (zh)
EA (1) EA009289B1 (zh)
GE (1) GEP20094699B (zh)
IS (1) IS7746A (zh)
MX (1) MXPA05003243A (zh)
NO (1) NO20052059L (zh)
NZ (1) NZ565990A (zh)
PL (1) PL377612A1 (zh)
RS (1) RS20050255A (zh)
UA (1) UA86749C2 (zh)
WO (1) WO2004028472A2 (zh)
ZA (1) ZA200502416B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028472A2 (en) * 2002-09-27 2004-04-08 Biogen Idec Ma Inc. THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
US8920808B2 (en) 2006-10-31 2014-12-30 East Carolina University Cytokine-based fusion proteins for treatment of multiple sclerosis
EP3348275A3 (en) 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
CN109134642A (zh) * 2011-10-01 2019-01-04 株式会社糖锁工学研究所 加成糖链的多肽及含有该多肽的医药组合物
GB201212878D0 (en) 2012-07-20 2012-09-05 Pike Justin Authentication method and system
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
GB201520760D0 (en) 2015-05-27 2016-01-06 Mypinpad Ltd And Licentia Group Ltd Encoding methods and systems
KR102454376B1 (ko) * 2018-07-04 2022-10-17 서울대학교산학협력단 신경손상의 면역세포치료

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
DE3712564A1 (de) * 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
DK1121156T3 (da) * 1998-10-16 2006-06-06 Biogen Idec Inc Polymerkonjugater af interferon-beta-1a samt deres anvendelse
BR9915548A (pt) * 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
JP2002537769A (ja) * 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
AU2002212107A1 (en) * 2000-11-02 2002-05-15 Maxygen Aps New multimeric interferon beta polypeptides
IL156059A0 (en) * 2001-02-27 2003-12-23 Maxygen Aps NEW INTERFERON beta-LIKE MOLECULES
AU2002254174A1 (en) * 2001-03-13 2002-09-24 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
WO2004028472A2 (en) * 2002-09-27 2004-04-08 Biogen Idec Ma Inc. THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β

Also Published As

Publication number Publication date
RS20050255A (en) 2007-08-03
EP1575531A2 (en) 2005-09-21
EP1575531B1 (en) 2011-08-17
CN1802170A (zh) 2006-07-12
BR0314548A (pt) 2005-08-09
AU2003277006A1 (en) 2004-04-19
KR20050059195A (ko) 2005-06-17
US20060182715A1 (en) 2006-08-17
JP2011132248A (ja) 2011-07-07
CA2500189A1 (en) 2004-04-08
EA200500545A2 (ru) 2005-08-25
AU2003277006B2 (en) 2009-09-10
EA009289B1 (ru) 2007-12-28
NZ565990A (en) 2009-10-30
AU2003277006C1 (en) 2010-04-01
EA200500545A3 (ru) 2007-04-27
PL377612A1 (pl) 2006-02-06
UA86749C2 (en) 2009-05-25
ZA200502416B (en) 2005-10-20
DK1575531T3 (da) 2011-11-21
WO2004028472A3 (en) 2006-01-19
EP1575531A4 (en) 2008-01-23
WO2004028472A2 (en) 2004-04-08
EP1575531B9 (en) 2012-02-22
JP2006513990A (ja) 2006-04-27
IS7746A (is) 2005-03-15
NO20052059D0 (no) 2005-04-27
ATE520412T1 (de) 2011-09-15
JP2007039463A (ja) 2007-02-15
MXPA05003243A (es) 2005-09-12
CN102038938A (zh) 2011-05-04
US20120058083A1 (en) 2012-03-08
GEP20094699B (en) 2009-06-10

Similar Documents

Publication Publication Date Title
NO20052059D0 (no) Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.
EA200500218A1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
NO20052923L (no) Fusjonerte bicykliske nitrogeninneholdende heteroringer
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
ATE304017T1 (de) Oxazolylpyrazol-derivate als kinase-inhibitoren
BRPI0415639A (pt) formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20050497L (no) Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
RS51821B (en) NEW COMBINED USE OF SULFONAMIDE UNITS IN CANCER TREATMENT
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
PL371736A1 (en) Method for administering glp-1 molecules
CY1108874T1 (el) ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ
MXPA04006572A (es) Terapia de combinacion antivirica.
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων
MY140194A (en) Novel fusidic acid derivatives
DK1708693T3 (da) Farmaceutiske sammensætninger indeholdende platinkomplekser med sekundære xanthater og terapeutiske anvendelser deraf
TW200510447A (en) Novel fusidic acid derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application